Subsequently, SAA was proposed as a possible serum biomarker for many cancers, including renal cell cancer, breast cancer, gastric cancer, oesophageal cancer, rectal cancer, hepatocellular cancer, pancreatic cancer, and nasopharyngeal carcinoma [15–20, 22–25]. This evidence concerns the gene SAA1 and renal cell adenocarcinoma.